- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00398307
Evaluating Patients With Varying Degrees of Renal Function
A Phase I, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients With Varying Degrees of Renal Function
This is a Phase I, open-label study evaluating the PK of S-1 components and their metabolites in patients with advanced solid tumors and varying degrees of renal function. Patients will be stratified by baseline 24-hour creatinine clearance(CrCL) into 4 cohorts using the normal clearance formula:
Group A: Control Group B:Mild renal dysfunction Group C:Moderate renal function and Group D: Severe renal dysfunction. Six patients will be enrolled into each cohort.
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85260
- Premiere Oncology of Arizona
-
-
California
-
Los Angeles, California, United States, 90033
- LAC/USC Medical Center
-
Santa Monica, California, United States, 90404
- Premiere Oncology
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Yale Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky/Division of Hematology/Oncology and Blood Marrow Transplantation
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland/Greenebaum Cancer Center
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131
- Cancer Research & Treatment Center/University of New Mexico
-
-
Texas
-
San Antonio, Texas, United States, 78245
- The Institute for Drug Development
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
A patient must meet all of the following inclusion criteria to be eligible for enrollment in this study:
- Has histologically or cytologically proven advanced solid tumors for which no standard therapy exists.
- Has provided written informed consent.
- Is 18 years of age or older.
- Is able to take medications orally.
- Has Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to ≤ 2 Appendix A,ECOG Performance Status).
Has adequate organ function as defined by the following criteria:
- Transaminases AST (SGOT) and ALT (SGPT) ≤ 2.5 times the upper limit of normal(ULN). If liver function abnormalities are due to underlying malignancy, then AST(SGOT) and ALT (SGPT) may be ≤ 5 times ULN.
- Total serum bilirubin ≤ 1.5 times ULN.
- Absolute granulocyte count ≥ 1,500/mm3 (ie, ≥ 1.5 x 109/L by International Units [IU]).
- Has a platelet count ≥ 100,000/mm3 (IU: ≥ 100 x 109/L).
- Has a hemoglobin value of ≥ 9.0 g/dL.
- Is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
3.3.2 Exclusion Criteria
Exclude a patient from this study if he/she does not fulfill the inclusion criteria, or if any of the following conditions are observed:
Has had treatment with any of the following within the specified time frame prior to study drug administration:
- Any investigational agent received either concurrently or within the last 30 days.
- Previous therapy for malignancy within 21 days, including any chemotherapy, immunotherapy, biologic or hormonal therapy (6 weeks for nitrosoureas or mitomycin(C).
- Previous radiotherapy within 14 days.
- Current enrollment in another clinical trial.
Has a serious illness or medical condition(s) including, but not limited to, the following:
- Myocardial infarction within the last 6 months, severe/unstable angina, congestive heart failure (New York Heart Association [NYHA] Class III or IV, Appendix E, NYHA Classification).
- Known (at the time of entry) gastrointestinal disorder, including malabsorption, chronic nausea, vomiting, or diarrhea present to the extent that it might interfere with oral intake and absorption of the study medication.
- Known brain metastasis.
- Known leptomeningeal metastases.
- Requires hemodialysis.
- Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome(AIDS)-related illness.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the Investigator would make the patient inappropriate for entry into this study.
Is receiving a concomitant treatment with drugs interacting with S-1. The following drugs are prohibited because there may be an interaction with S-1:
- Sorivudine, uracil, dipyridamole, cimetidine and folinic acid (may enhance S-1 activity).
- Allopurinol (may diminish S-1 activity).
- Phenytoin (S-1 may enhance phenytoin activity).
- Flucytosine, a fluorinated pyrimidine antifungal agent (may enhance S-1 and flucytosine activity).
- Pilocarpine (may inhibit CYP2A6 activity).
- Has known sensitivity to 5-FU.
- Is a pregnant or lactating female.
- Is a patient with reproductive potential who refuses to use an adequate means of contraception
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To provide specific dosing recommendations for S-1 in patients with renal impairment based on the PK of S-1 and its components after single dose and steady state conditions.
Time Frame: The Pharmacokinetic Phase (Part 1) of the study will last 24 days.
|
The Pharmacokinetic Phase (Part 1) of the study will last 24 days.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assess Anti-tumor activity, and safety profile of S-1 in patients with impaired renal function
Time Frame: Each cycle of the Extension Phase (Part 2) will be 21 days (14 days of S-1 treatment, 7 days recovery). The end of study for the Extension Phase will be 30 days after the last dose of S-1.
|
Each cycle of the Extension Phase (Part 2) will be 21 days (14 days of S-1 treatment, 7 days recovery). The end of study for the Extension Phase will be 30 days after the last dose of S-1.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TPU-S1111
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Impairment
-
Eisai Inc.CompletedHepatic Impairment; Renal ImpairmentUnited States
-
JW PharmaceuticalCompletedHealthy, Renal ImpairmentKorea, Republic of
-
Kowa Research Institute, Inc.CompletedSevere Renal ImpairmentUnited States
-
Centre for Probe Development and CommercializationSt. Joseph's Healthcare Hamilton; McMaster UniversityCompleted
-
Gilead SciencesTerminatedSevere Renal ImpairmentUnited States
-
Sichuan Haisco Pharmaceutical Group Co., LtdThe First Affiliated Hospital of Zhengzhou UniversityCompletedChronic Renal ImpairmentChina
-
Novartis PharmaceuticalsCompletedMild and Moderate Renal ImpairmentRussian Federation, Germany, Serbia
-
Idorsia Pharmaceuticals Ltd.CompletedHealthy Subjects | Severe Renal ImpairmentCzechia
-
Melbourne HealthWithdrawnRenal Impairment After Cardiac SurgeryAustralia
-
AstraZenecaCompletedRenal Impairment | Hepatic ImpairmentBulgaria
Clinical Trials on S-1/Cisplatin
-
Kyungpook National University HospitalUnknownGastric CancerKorea, Republic of
-
Mianyang Central HospitalUnknownEsophageal Squamous Cell CarcinomaChina
-
Asan Medical CenterNational Cancer Center, Korea; Chonbuk National University Hospital; Samsung... and other collaboratorsCompletedAdvanced Gastric CancerKorea, Republic of
-
Taiho Oncology, Inc.Completed
-
Taiho Oncology, Inc.Completed
-
Taiho Oncology, Inc.Quintiles, Inc.Completed
-
Taiho Pharmaceutical Co., Ltd.CompletedCervical CancerJapan, Korea, Republic of, Taiwan
-
Taiho Pharmaceutical Co., Ltd.Completed
-
Min-Hee RyuCompletedGastric CancerKorea, Republic of
-
Tang-Du HospitalUnknownStage IV Gastric CancerChina